Dale Conaway
Directeur/Membre du Conseil chez BIOXYTRAN, INC.
Fortune : 126 376 $ au 30/04/2024
Postes actifs de Dale Conaway
Sociétés | Poste | Début | Fin |
---|---|---|---|
BIOXYTRAN, INC. | Directeur/Membre du Conseil | 02/11/2018 | - |
Independent Dir/Board Member | 02/11/2018 | - | |
Office of Research Oversight | Directeur Technique/Scientifique/R&D | - | - |
Historique de carrière de Dale Conaway
Anciens postes connus de Dale Conaway
Sociétés | Poste | Début | Fin |
---|---|---|---|
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Directeur/Membre du Conseil | - | 03/08/2018 |
Independent Dir/Board Member | - | 03/08/2018 | |
NANOMIX CORPORATION | Directeur/Membre du Conseil | 01/09/2009 | 15/09/2016 |
Independent Dir/Board Member | 26/03/2012 | 15/09/2016 | |
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Directeur/Membre du Conseil | 10/02/2010 | 30/11/2010 |
GALECTIN THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/05/2001 | 12/02/2009 |
Federal Research, Inc. | Corporate Officer/Principal | 01/01/2001 | 02/01/2006 |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Directeur/Membre du Conseil | 01/01/1998 | 01/02/2001 |
Michigan Department of Agriculture | Corporate Officer/Principal | 01/01/1998 | 01/01/2001 |
Formation de Dale Conaway
Tuskegee University | Doctorate Degree |
Michigan State University | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 11 |
2 |
Opérationnelle
Director/Board Member | 6 |
Independent Dir/Board Member | 3 |
Corporate Officer/Principal | 2 |
Sectorielle
Health Technology | 6 |
Consumer Services | 3 |
Government | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GALECTIN THERAPEUTICS INC. | Health Technology |
Entreprise privées | 8 |
---|---|
Avanyx Therapeutics, Inc.
Avanyx Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avanyx Therapeutics, Inc. engages in the development, manufacture and marketing of therapeutic drugs with a focus on glyco-pathology, a specialized field involving understanding the importance of Glycoproteins in biochemistry and progression of diseases. The company is headquartered in Newton, MA | Health Technology |
Michigan Department of Agriculture | Government |
Boston Therapeutics, Inc.
Boston Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Lawrence, MA. | Health Technology |
Office of Research Oversight | |
Oxygen Therapy, Inc.
Oxygen Therapy, Inc. Pharmaceuticals: MajorHealth Technology Oxygen Therapy, Inc. is an early stage pharmaceutical company, which engages in the development, manufacture, and commercialization of an innovative platform of oxygen therapeutic treatments for hypoxic conditions and necrosis prevention. Its product pipeline includes OTI-629, an anti-necrosis drug; and OTI-1011, a resuscitative agent for wound healing applications. The company was founded by David Platt on May 20, 2016 and is headquartered Newton, MA. | Health Technology |
BioXyTran, Inc. /Old/
BioXyTran, Inc. /Old/ Pharmaceuticals: MajorHealth Technology BioXyTran, Inc. operates as a biopharmaceutical company. The firm focuses on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. The company was founded in 2017 and is headquartered in Newton, MA. | Health Technology |
BioXyTran, Inc. | |
Federal Research, Inc. |
- Bourse
- Insiders
- Dale Conaway
- Expérience